METASTATIC RENAL CELL CARCINOMA ( MRCC)
Clinical trials for METASTATIC RENAL CELL CARCINOMA ( MRCC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC RENAL CELL CARCINOMA ( MRCC) trials appear
Sign up with your email to follow new studies for METASTATIC RENAL CELL CARCINOMA ( MRCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced kidney cancer: experimental drug enters human trials
Disease control Recruiting nowThis study tests a new medicine, PF-08634404, in adults with advanced kidney cancer that has spread. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer drugs. About 224 participants who have not had prior treatment for their advanced…
Matched conditions: METASTATIC RENAL CELL CARCINOMA ( MRCC)
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for kidney cancer: triple-drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests three different drug combinations in 120 people with advanced kidney cancer that has spread. The goal is to see which combination works best to shrink tumors. Participants will receive either a new two-drug or three-drug combination, or a standard two-drug therap…
Matched conditions: METASTATIC RENAL CELL CARCINOMA ( MRCC)
Phase: PHASE2 • Sponsor: Brian Rini • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Triple attack on kidney cancer: immune booster, radiation, and immunotherapy
Disease control Recruiting nowThis study tests whether adding an immune-boosting drug (IMSA101) and targeted radiation to standard immunotherapy can help control metastatic kidney cancer that has started to grow again. About 15 adults with clear cell kidney cancer that has progressed in up to 5 spots will rec…
Matched conditions: METASTATIC RENAL CELL CARCINOMA ( MRCC)
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Could a PET scan let kidney cancer patients pause treatment?
Disease control Recruiting nowThis phase 2 trial is testing whether PET/CT scans can safely guide treatment pauses in people with advanced kidney cancer. Participants who have responded well to at least 12 months of standard therapy (immunotherapy plus targeted drugs) will stop treatment and be monitored with…
Matched conditions: METASTATIC RENAL CELL CARCINOMA ( MRCC)
Phase: PHASE2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jun 26, 2026 17:33 UTC
-
Global study digs into immunotherapy success in kidney cancer
Knowledge-focused Recruiting nowThis study gathers information from over 1,200 people worldwide who have metastatic kidney cancer and received immunotherapy as their first treatment. Researchers will look at how long patients live, how well tumors shrink, and what genetic or immune factors might predict better …
Matched conditions: METASTATIC RENAL CELL CARCINOMA ( MRCC)
Sponsor: Hospital of Macerata • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC